← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2017Last known activity
Oct 1, 2025
Timeline
No events for the selected filters.
Drugs by trial phase (7 distinct, 6 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
Recent trials (16)
- NCT07255326Lead sponsorN/AOct 1, 2025
- NCT07255326Sponsor investigatorN/AOct 1, 2025
- NCT06659406OfficialN/AJan 1, 2025
- NCT06659406Lead sponsorN/AJan 1, 2025
- NCT06659406Sponsor investigatorN/AJan 1, 2025
- NCT06637384Sponsor investigatorPhase 4Mar 1, 2024
- NCT06637384Lead sponsorPhase 4Mar 1, 2024
- NCT06637384OfficialPhase 4Mar 1, 2024
- NCT05425914Overall official - principal investigatorPhase 3Nov 1, 2021
- NCT05425914Lead sponsorPhase 3Nov 1, 2021
- NCT05425914Reponsible party - principal investigatorPhase 3Nov 1, 2021
- NCT04970329Reponsible party - principal investigatorN/AJul 31, 2021
- NCT04970329Lead sponsorN/AJul 31, 2021
- NCT03237533Study directorEarly Phase 1Jun 1, 2017
- NCT03237533Reponsible party - principal investigatorEarly Phase 1Jun 1, 2017
Details
- Last known activity
- Oct 1, 2025